1. Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)
- Author
-
Il Suk Sohn, Sang-Hyun Ihm, Gee Hee Kim, Sang Min Park, Bum-Kee Hong, Chang Hoon Lee, Sang Hyun Lee, Dae-Il Chang, Sung-Pil Joo, Sang-Chan Lee, Yong-ho Lee, Dong Woon Jeon, Kyung Tae Jung, Si Jae Rhee, Yoon-Jin Cho, Chong-Jin Kim, and Investigators
- Subjects
Hypertension ,Observational study ,Olmesartan ,Amlodipine ,Hydrochlorothiazide ,Real-world ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Abstract Background In this prospective, multicenter, non-comparative observational study, the effectiveness and safety of the triple single-pill combination (SPC) of olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) were evaluated in a real clinical practice setting in Korean patients with essential hypertension. Methods A total of 3752 patients were enrolled and followed for 12 months after administration of OM/AML/HCTZ. Primary endpoint was change from baseline to month 6 in the mean systolic blood pressure (SBP). Secondary endpoints included changes from baseline in the mean SBP at month 3, 9, 12 and the mean diastolic blood pressure (DBP) at month 3, 6, 9, 12; changes in the mean SBP/DBP according to age and underlying risk factors; and blood pressure control rate (%) at different time points. Adherence to and satisfaction with OM/AML/HCTZ treatment among patients and physicians were assessed by medication possession ratio (MPR) and numeric rating scale, respectively, as exploratory endpoints. Safety was evaluated by the incidence and severity of adverse events (AEs) as well as the discontinuation rate due to AEs. Results OM/AML/HCTZ administration led to significant reductions in the mean SBP/DBP by 11.5/6.6, 12.3/7.0, 12.3/7.2, and 12.8/7.4 mmHg from baseline to month 3, 6, 9 and 12, respectively (P
- Published
- 2021
- Full Text
- View/download PDF